Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19715686 | 0.84 | GABRA5 (0.37) | SMN1; SMN2NPC1RAB9AALDH1A1GAA | |
| SCHEMBL12990170 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2NPC1RAB9AALDH1A1ADORA1 | |
| SCHEMBL2683463 | 0.83 | GABRA5 (0.46) | PTGS2SMN1; SMN2ALDH1A1KMT2APOLB | |
| SCHEMBL15543509 | 0.76 | CYP1A2 (0.38) | PTGS2NPC1RAB9AALDH1A1GAA | |
| SCHEMBL12523116 | 0.73 | NPC1 (0.47) | SMN1; SMN2NPC1RAB9AALDH1A1KEAP1 | |
| SCHEMBL822713 | 0.73 | KEAP1 (0.45) | SMN1; SMN2NPC1RAB9AALDH1A1BRD4 | |
| SCHEMBL15636198 | 0.72 | BRD4 (0.42) | PTGS2SMN1; SMN2ADKALDH1A1BRD4 | |
| SCHEMBL17844431 | 0.72 | NPC1 (0.42) | SMN1; SMN2NPC1RAB9AALDH1A1BRD4 | |
| SCHEMBL16708689 | 0.71 | POLB (0.45) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL4764875 | 0.71 | KDR (0.52) | PTGS2NPC1RAB9AADKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025098545-A1 | NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I. (CZ) | 2025-05-15 | — | — | WO | disclosed |
| EP-4553080-A1 | NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) | 2025-05-14 | — | — | EP | disclosed |
| CN-103221402-B | Triazole derivatives and their use for neurological disorders | HOFFMANN LA ROCHE | 2015-06-17 | — | — | CN | disclosed |
| EP-2638029-B1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-8742097-B2 | Triazole compounds I | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2638029-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| CN-103221402-A | Triazole derivatives and their use for neurological disorders | HOFFMANN LA ROCHE | 2013-07-24 | — | — | CN | disclosed |
| WO-2012062687-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | GABRA5, GABRA3, GABRA1 | PTGS2 2516/4885SMN1; SMN2 4703/4885NPC1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.